The global cancer monoclonal antibody testing market size was $55,640.00 million in 2021 and is predicted to grow with a CAGR of 7.0%, by generating a revenue of $106,825.10 million by 2031.
Monoclonal antibodies are synthetic antibodies that are directed against specific sites in the human body. On the surface of the cancer-causing cells, they serve as antigens. There are numerous monoclonal antibodies, and each one is made to solely attach to one kind of antigen. These antibodies are frequently used to treat a number of illnesses, including some forms of cancer. They deliver radioactive materials or injectable medications directly to the cancer cells. According to a study, radioactive cancer therapy is the most often used type of cancer therapy worldwide.
The increase in the geriatric population, rise in the incidence of cancer, and increase in demand for novel vaccines and therapies are some of the primary factors anticipated to drive the cancer monoclonal antibody testing market growth. The demand for effective therapies has increased owing to the rise in prevalence of different types of cancer like lung cancer, around the world, prompting researchers and scientists to accelerate their research efforts and produce effective monoclonal drugs for cancer. These factors are projected to drive the market growth during the forecast period.
The market is significantly constrained by the high costs associated with the creation of monoclonal antibodies using cutting-edge technology. The complicated manufacturing procedure, pricey biological and chemical components, clinical trials, as well as necessary efficacy, safety, and quality tests, are the main causes of the high cost of cancer monoclonal antibody testing. Large-scale synthesis of monoclonal antibodies involving many disulfide bonds and post-translational modifications necessitates the use of expensive, specialized equipment. All these are the major factors projected to hamper the market growth during the forecast period.
Governments of various countries around the world are investing in the development of advanced cancer diagnosis and treatment methods, which is expected to boost the growth of the cancer monoclonal antibody testing market. Furthermore, many countries have established programs and initiatives aimed at providing access to cancer care for their citizens, further driving the demand for cancer monoclonal antibody tests. The increase in government support is also driving the development of new cancer monoclonal antibody tests, which are more accurate, reliable, and cost-effective. This is leading to a rise in the number of cancer patients being diagnosed at an early stage, which is increasing the demand for cancer monoclonal antibody tests. This contributes to the market rise in the cancer monoclonal antibody testing market.
The COVID-19 pandemic has had a negative impact on the cancer monoclonal antibody testing industry. During the initial phase of the pandemic, the coronavirus 2019 (COVID-19), caused significant challenges in the supply of materials, production, and logistical operations, and significantly impacted research and drug development activities. When the COVID-19 pandemic began, most businesses and research initiatives around the world suspended operations, reducing market demand for reagents and other laboratory equipment.
The key players profiled in this report include F. Hoffmann-La Roche Ltd., Bristol Myers, Squibb Co., Merck & Co., GlaxoSmithKline plc, Johnson & Johnson, Amgen, Inc., Novartis AG, AstraZeneca plc, Eli Lilly and Company, and AbbVie.
Monoclonal antibodies are synthetic antibodies that are directed against specific sites in the human body. On the surface of the cancer-causing cells, they serve as antigens. There are numerous monoclonal antibodies, and each one is made to solely attach to one kind of antigen. These antibodies are frequently used to treat a number of illnesses, including some forms of cancer. They deliver radioactive materials or injectable medications directly to the cancer cells. According to a study, radioactive cancer therapy is the most often used type of cancer therapy worldwide.
The increase in the geriatric population, rise in the incidence of cancer, and increase in demand for novel vaccines and therapies are some of the primary factors anticipated to drive the cancer monoclonal antibody testing market growth. The demand for effective therapies has increased owing to the rise in prevalence of different types of cancer like lung cancer, around the world, prompting researchers and scientists to accelerate their research efforts and produce effective monoclonal drugs for cancer. These factors are projected to drive the market growth during the forecast period.
The market is significantly constrained by the high costs associated with the creation of monoclonal antibodies using cutting-edge technology. The complicated manufacturing procedure, pricey biological and chemical components, clinical trials, as well as necessary efficacy, safety, and quality tests, are the main causes of the high cost of cancer monoclonal antibody testing. Large-scale synthesis of monoclonal antibodies involving many disulfide bonds and post-translational modifications necessitates the use of expensive, specialized equipment. All these are the major factors projected to hamper the market growth during the forecast period.
Governments of various countries around the world are investing in the development of advanced cancer diagnosis and treatment methods, which is expected to boost the growth of the cancer monoclonal antibody testing market. Furthermore, many countries have established programs and initiatives aimed at providing access to cancer care for their citizens, further driving the demand for cancer monoclonal antibody tests. The increase in government support is also driving the development of new cancer monoclonal antibody tests, which are more accurate, reliable, and cost-effective. This is leading to a rise in the number of cancer patients being diagnosed at an early stage, which is increasing the demand for cancer monoclonal antibody tests. This contributes to the market rise in the cancer monoclonal antibody testing market.
The COVID-19 pandemic has had a negative impact on the cancer monoclonal antibody testing industry. During the initial phase of the pandemic, the coronavirus 2019 (COVID-19), caused significant challenges in the supply of materials, production, and logistical operations, and significantly impacted research and drug development activities. When the COVID-19 pandemic began, most businesses and research initiatives around the world suspended operations, reducing market demand for reagents and other laboratory equipment.
The key players profiled in this report include F. Hoffmann-La Roche Ltd., Bristol Myers, Squibb Co., Merck & Co., GlaxoSmithKline plc, Johnson & Johnson, Amgen, Inc., Novartis AG, AstraZeneca plc, Eli Lilly and Company, and AbbVie.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the cancer monoclonal antibodies market analysis from 2021 to 2031 to identify the prevailing cancer monoclonal antibodies market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the cancer monoclonal antibodies market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global cancer monoclonal antibodies market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By End User
- Hospitals and Clinics
- Research and Academic Institute/Laboratories
By Antibody Type
- Murine
- Chimeric
- Humanized
By Application
- Blood Cancer
- Breast Cancer
- Lung Cancer
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- UAE
- South Africa
- Rest of LAMEA
Key Market Players
- Roche Holdings Ltd
- Johnson & Johnson
- Pfizer Inc.
- Novartis AG
- AstraZeneca plc
- Merck & Co. Inc.
- Celgene Limited
- Bistrol-Myers Squibb
- Eli Lilly & Co.
- Abbvie Inc
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE
CHAPTER 5: CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION
CHAPTER 6: CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER
CHAPTER 7: CANCER MONOCLONAL ANTIBODIES MARKET, BY REGION
CHAPTER 8: COMPETITIVE LANDSCAPE
CHAPTER 9: COMPANY PROFILES
List of Tables
List of Figures
Executive Summary
According to the report titled, “Cancer Monoclonal Antibodies Market," the cancer monoclonal antibodies market was valued at $55.6 billion in 2021, and is estimated to reach $106.8 billion by 2031, growing at a CAGR of 7% from 2022 to 2031.Cancer is the body's unchecked proliferation of aberrant cells. When the body's natural control system malfunctions, cancer might emerge. Instead of dying, old cells proliferate uncontrollably to produce new, aberrant cells. These excess cells could aggregate into a tissue mass known as a tumor. Leukemia is one type of cancer that does not produce tumors. Immune system proteins called monoclonal antibodies are made in laboratories. A person’s body naturally produces antibodies, which assist the immune system in identifying pathogenic microorganisms like bacteria and viruses and identifying them for eradication. Monoclonal antibodies are specific target-recognizers, just like the body's own antibodies.
Cancer is frequently treated using monoclonal antibodies. Monoclonal antibodies are within the category of targeted cancer therapy, which means that they are made to interact with targets. Some monoclonal antibodies are also used in immunotherapy because they assist the body fight cancer by activating the immune system. As an illustration, certain monoclonal antibodies label cancer cells to help the immune system more easily identify and eliminate them. As an illustration, consider the drug rituximab, which activates the immune system by binding the protein CD20 on B cells and some varieties of cancer cells. A type of white blood cell is B cells.
The market for cancer monoclonal antibody testing is expected to expand as cancer cases increase globally. For instance, according to a survey conducted by the American Cancer Society in January 2022, it is expected that every year, approximately 1.9 million new cancer cases are diagnosed and 609,360 cancer-related deaths occur in the U.S., which is about 1,670 mortality every day. Lung, prostate, bowel, and female breast cancer make up the four most prevalent cancer types worldwide, each of which accounts for 43% of all new cancer cases. Therefore, it is projected that the market for cancer monoclonal antibody testing would grow in popularity as cancer incidence rates rise internationally.
A considerable emphasis on the R&D of monoclonal antibody therapeutics to provide highly focused medication therapy for challenging and severe illnesses will increase the market growth potential for monoclonal antibodies. Government support and regulatory approvals would tremendously benefit companies looking to expand the monoclonal antibody market.
Governments all over the world have been forced to invest a significant investment in laboratories to produce extremely effective monoclonal antibodies for cancer treatment due to the surge in cancer incidence. Governments of various countries have also boosted the rate at which they approve monoclonal antibodies, which will open up a wide range of business potential in the years to come. Strategic partnerships are helping companies in the cancer monoclonal antibody testing market innovate their products more frequently. Companies are creating novel products and exchanging knowledge and expertise with other businesses in order to survive in the fiercely competitive industry. Companies have traditionally worked together with academic and research institutions in this sector through alliances and in- or out-licensing agreements, but in recent years, this trend has grown.
The cancer monoclonal antibody market is segmented on the basis of antibody type, application, end user, and region. By antibody type, the market has been divided into murine, chimeric, and humanized. By application, the market has been divided into blood cancer, breast cancer, lung cancer, and others. By end user, the market has been divided into hospitals & clinics and research & academic institutes/laboratories. On the basis of region, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and rest of Europe), Asia-Pacific (China, India, Japan, Australia, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, UAE, and rest of LAMEA).
The key players profiled in this report include F. Hoffmann-La Roche Ltd., Bristol Myers, Squibb Co., Merck & Co., GlaxoSmithKline plc, Johnson & Johnson, Amgen, Inc., Novartis AG, AstraZeneca plc, Eli Lilly and Company, and AbbVie. The players in the market are actively engaged in the adoption of various strategies such as acquisitions, product launches, and expansion to remain competitive and gain an advantage over competitors in the market. For instance, on December 27, 2022, ZB131 has been given the Orphan Drug designation by the Food and Drug Administration (FDA) for the treatment of pancreatic cancer. ZB131 is a monoclonal antibody that has been developed exclusively for the highly specific and affine targeting of cancer-specific plectin (CSP). Unlike CSP, which is generally located in the cytoplasm of healthy cells, plectin has been discovered on the surface of cancer cells, where it acts as an accelerator of metastasis and tumor growth.
Key Market Insights
- By antibody type, the murine sub-segment emerged as the global leader in 2021 and the humanized sub-segment is anticipated to have the fastest growth during the forecast time
- By application, the blood cancer sub-segment emerged as the global leader in 2021 and the lung cancer sub-segment is anticipated to have the fastest growth during the forecast period
- By end user, the hospitals & clinics segment had a dominant market share in 2021 and is predicted to show the fastest growth in the upcoming years
- Based on region, North America was the highest revenue contributor to the market in 2021, accounting for a market size of $23,023.8 million
Companies Mentioned
- Roche Holdings Ltd
- Johnson & Johnson
- Pfizer Inc.
- Novartis AG
- AstraZeneca plc
- Merck & Co. Inc.
- Celgene Limited
- Bistrol-Myers Squibb
- Eli Lilly & Co.
- Abbvie Inc
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Related Reports
Cancer Monoclonal Antibodies - Market Insights, Competitive Landscape, and Market Forecast - 2030
- Report
- 150 Pages
- Global
From
Cancer Monoclonal Antibodies Market by Type, Application, End-user - Global Forecast 2025-2030
- Report
- 192 Pages
- Global
From
Cancer Monoclonal Antibodies Global Market Report 2024
- Report
- 250 Pages
- Global
From
From
Breast Cancer Monoclonal Antibodies Global Market Report 2024
- Report
- 250 Pages
- Global
From
This product is a market research report. Each license type allows a set number of users to access the report. Please select an option from the list below. This product is a market research report. This is a single user license, allowing one user access to the product. This product is a market research report. This is a single user license, allowing one user access to the product. The product is a PDF. This product is a market research report. This is an enterprise license, allowing all employees within your organization access to the product. The product is a PDF. 
